Published in Eur J Clin Pharmacol on June 19, 2010
From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine. EPMA J (2013) 0.98
CT perfusion of the liver: principles and applications in oncology. Radiology (2014) 0.92
Revitalizing personalized medicine: respecting biomolecular complexities beyond gene expression. CPT Pharmacometrics Syst Pharmacol (2014) 0.78
Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study. Eur Radiol (2015) 0.77
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med (2008) 9.75
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA (2009) 7.78
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood (2004) 4.70
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst (2007) 3.85
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther (2007) 3.60
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet (2005) 2.97
Pharmacogenomics and individualized drug therapy. Annu Rev Med (2006) 2.95
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2009) 2.78
Large scale association analysis of novel genetic loci for coronary artery disease. Arterioscler Thromb Vasc Biol (2009) 2.71
High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther (2009) 2.44
Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics (2004) 2.32
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation (2009) 2.20
Harmonization of molecular monitoring of CML therapy in Europe. Leukemia (2009) 1.76
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One (2009) 1.48
Pharmacogenetics-based therapeutic recommendations--ready for clinical practice? Nat Rev Drug Discov (2005) 1.35
The Personalized Medicine Coalition: goals and strategies. Am J Pharmacogenomics (2005) 1.32
The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vascul Pharmacol (2006) 1.13
Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J (2006) 1.11
Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. BMC Med Genomics (2010) 1.09
Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice. Pharmacogenomics (2010) 1.08
Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J (2009) 1.06
Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions. Rev Recent Clin Trials (2007) 0.92
Pharmacogenetics in psychiatry--a useful clinical tool or wishful thinking for the future? Curr Pharm Des (2010) 0.90
Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br J Haematol (2010) 0.87
Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. Int Clin Psychopharmacol (2009) 0.83
The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther (2007) 0.80
Integrating phenotypic data for depression. J Integr Bioinform (2010) 0.80
Providing patients with information on pharmacogenetic testing. Nurs Stand (2009) 0.76
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology (2003) 2.97
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther (2002) 2.01
CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther (2004) 1.99
Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol (2010) 1.96
Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics (2002) 1.75
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther (2002) 1.58
Functional significance of a hereditary adenine insertion variant in the 5'-UTR of the endothelin-1 gene. Pharmacogenetics (2003) 1.51
MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol (2007) 1.45
Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother (2005) 1.42
The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2004) 1.42
Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev (2003) 1.40
CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis (2003) 1.28
The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther (2002) 1.23
CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation. Carcinogenesis (2002) 1.23
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol (2003) 1.20
Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics (2008) 1.18
Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry (2010) 1.16
Educating European (junior) doctors for safe prescribing. Basic Clin Pharmacol Toxicol (2007) 1.15
Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos (2005) 1.14
CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer (2003) 1.13
The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart. J Histochem Cytochem (2005) 1.10
[Hypoglycemic risk of insulinotropic drugs]. Med Monatsschr Pharm (2009) 1.05
Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther (2004) 1.05
Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control (2003) 1.04
A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.04
Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients. PLoS One (2011) 1.02
Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics (2009) 1.02
Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol Pharmacol (2011) 1.01
MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol (2002) 0.99
Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther (2006) 0.99
miRNAs as mediators of drug resistance. Epigenomics (2012) 0.98
Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis. Genet Med (2007) 0.94
Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol (2014) 0.94
Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study. Mutat Res (2005) 0.94
High DNA damage by benzo[a]pyrene 7,8-diol-9,10-epoxide in bronchial epithelial cells from patients with lung cancer: comparison with lung parenchyma. Cancer Lett (2004) 0.91
MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics (2012) 0.90
Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. Am J Pathol (2003) 0.90
Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. Eur J Clin Pharmacol (2011) 0.90
Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics (2004) 0.90
OpenVigil--free eyeballs on AERS pharmacovigilance data. Nat Biotechnol (2012) 0.90
Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J Histochem Cytochem (2002) 0.89
Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. Int J Cancer (2004) 0.89
Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme. BMC Cancer (2013) 0.89
Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus. Ther Drug Monit (2015) 0.89
Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol (2004) 0.87
Antimicrobial peptides and proteins of the horse--insights into a well-armed organism. Vet Res (2011) 0.86
Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology (2004) 0.85
Endothelial NO synthase polymorphisms and postural tachycardia syndrome. Hypertension (2005) 0.85
Endothelial nitric oxide synthase Glu(298)-->Asp polymorphism, carotid atherosclerosis and intima-media thickness in a general population sample. Clin Sci (Lond) (2005) 0.84
Identification and functional analysis of genetic variants of the human beta-glucuronidase in a German population sample. Pharmacogenet Genomics (2005) 0.83
MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol (2014) 0.83
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res (2013) 0.82
Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol (2006) 0.82
Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. Basic Clin Pharmacol Toxicol (2010) 0.82
Pharmacogenetics-based new therapeutic concepts. Drug Metab Rev (2004) 0.81
Differential expression and functionality of TRPA1 protein genetic variants in conditions of thermal stimulation. J Biol Chem (2012) 0.81
Analysis of alternative promoter usage in expression of HSD11B1 including the development of a transcript-specific quantitative real-time PCR method. Chem Biol Interact (2011) 0.81
Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus. Pharmacogenetics (2002) 0.81
Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet Genomics (2011) 0.81
Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. Pharmacogenomics (2009) 0.81
Clinical implementation of pharmacogenetics: a nonrepresentative explorative survey to participants of WorldPharma 2010. Pharmacogenomics (2011) 0.80
Endothelial nitric oxide synthase Glu298Asp gene polymorphism, blood pressure and hypertension in a general population sample. J Hypertens (2005) 0.80
'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility. Cancer Lett (2005) 0.80
HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenet Genomics (2016) 0.79
Association between the N-acetylation genetic polymorphism and bronchial asthma. Br J Clin Pharmacol (2002) 0.79
Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. Clin Ther (2010) 0.79
Risk of coronary artery disease as influenced by variants of the human endothelin and endothelin-converting enzyme genes. Pharmacogenet Genomics (2007) 0.79
Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. Clin Pharmacol Ther (2002) 0.78
Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia (2008) 0.78
Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379. Pharmacogenet Genomics (2014) 0.78
Influence of an insertion variant in the 5'UTR of the endothelin-1 gene on orthostatic intolerance. Am J Med Sci (2005) 0.77
Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms? J Clin Psychopharmacol (2005) 0.77
Beta 2-adrenergic receptor polymorphism and susceptibility to primary congenital and primary open angle glaucoma. Eur J Clin Pharmacol (2003) 0.77
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis (2010) 0.77
Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. Eur J Clin Pharmacol (2004) 0.76
Conference Scene: Pharmacogenomics at the second PharmSciFair 2009: adverse drug reactions and clinical implementation. Pharmacogenomics (2009) 0.76
Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis. Liver Int (2006) 0.76
Opportunities and limitations: the value of pharmacogenetics in clinical practice. Br J Clin Pharmacol (2014) 0.75
Interaction of CA repeat polymorphism of the endothelial nitric oxide synthase and hyperhomocysteinemia in acute coronary syndromes: evidence of gender-specific differences. J Mol Med (Berl) (2003) 0.75
Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PLoS One (2017) 0.75
Correspondence (reply): In Reply. Dtsch Arztebl Int (2013) 0.75
Highlights from the latest articles in breast cancer pharmacogenomics. Pharmacogenomics (2012) 0.75
Regulation's threat to research. A UK problem. BMJ (2008) 0.75
Conference Scene: Pharmacogenomic highlights of the DGPT Annual Congress. Pharmacogenomics (2012) 0.75
Pharmacogenomics in acute coronary syndrome. Expert Opin Pharmacother (2008) 0.75
5th Anniversary meeting of the European Research Network Pharmacogenetics/Pharmacogenomics. 8-9 December 2011, Utrecht, The Netherlands. Pharmacogenomics (2012) 0.75
Functional characterization of protein variants encoded by nonsynonymous single nucleotide polymorphisms in MARC1 and MARC2 in healthy Caucasians. Drug Metab Dispos (2014) 0.75
A functional serotonin transporter (SLC6A4) polymorphism modifies the association of smoking and diabetes with asymptomatic carotid atherosclerosis. Thromb Haemost (2005) 0.75
Identification of twelve polymorphisms in the endothelin-1 gene by use of fluorescently labeled oligonucleotides and PCR with restriction fragment polymorphism analysis. Clin Chem (2004) 0.75